| Date | Title | Description |
| 16.07.2026 | Frost & Sullivan Celebrates 65 Years of Transformational Growth with an Exclusive Executive Leadership Banquet | Executive networking, strategic dialogue, and industry recognition mark a milestone anniversary celebrating innovation and transformational growth.
SAN ANTONIO, July 16, 2026 /PRNewswire/ -- Frost & Sullivan proudly celebrated its 65th ... |
| 12.05.2026 | Avance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership | The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the global biotechnology CRO market
SAN ANTONIO, May 12, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce... |
| 28.06.2025 | Frost & Sullivan Recognizes Leading Organizations with Prestigious 2025 Best Practices Awards | Frost & Sullivan celebrates companies for their outstanding achievements at the Frost & Sullivan Best Practices Awards Gala
SAN ANTONIO, June 28, 2025 /PRNewswire/ -- The best in business gathered in Los Angeles, California, at the ... |
| 14.05.2025 | Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services | This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials.
SAN ANTONIO, May 14, 2025 /PRNewswire/ -- Frost & Sullivan has named Avance C... |
| 16.03.2025 | Avance Clinical 與四個優質的台灣試驗單位簽訂諒解備忘錄，加強對美國生物科技公司的全球影響力 | 台北，台灣及阿德萊德，澳洲, March 17, 2025 (GLOBE NEWSWIRE) -- Avance Clinical 是一家全球頂尖的全方位服務受託研究機構 (CRO)，專門提供優質而靈活的臨床生物科技研究服務。該公司欣然宣佈本週與四個台灣主要的臨床試驗單位簽署了諒解備忘錄 (MOU)。 這些新的合作夥伴關係標誌著 Avance Clinical 在台灣的策略擴展，鞏固了該公司致力為美國生物科技公司在亞太區提供優質臨床研究解決方案的承諾。
Avance Clin... |
| 16.03.2025 | Global Reach for US Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites | TAIPEI, Taiwan and ADELAIDE, Australia, March 17, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, is please... |
| 16.03.2025 | 助力美国生物科技公司全球扩张：Avance Clinical 与四家台湾一流试验机构签订 MOU | 台湾台北和澳大利亚阿德莱德, March 17, 2025 (GLOBE NEWSWIRE) -- 全球领先的全方位服务合同研究组织 (CRO) Avance Clinical 专注于高质量且灵活的临床生物科技研究服务。本周，Avance Clinical 欣然宣布与台湾重要临床试验机构签署了四项谅解备忘录 (MOU)。 这些新建立的合作伙伴关系标志着向台湾进行的战略扩张，再一次印证 Avance Clinical 为美国生物科技公司提供亚太地区高质量临床研究解决方案的决心。... |
| 13.09.2024 | Avance Clinical Joins the Australian Clinical Trials Roadshow, Sharing Cost and Time Benefits for Early-Phase US Biotechs | WAKE FOREST, N.C. and ADELAIDE, Australia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the market-leading CRO for biotechs, announced today that Avance Clinical will represent the CRO sector at the Australian Clinical Trials Roadsho... |
| 04.09.2024 | Avance Clinical GlobalReady Site Partnership Network wächst schnell auf 2.000 Mitglieder an | WAKE FOREST, North Carolina und ADELAIDE, Australien, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, das preisgekrönte marktführende Auftragsforschungsinstitut für Biotechnologieunternehmen, gab heute bekannt, dass sich 2.000 klinische... |
| 04.09.2024 | Le réseau de partenariat de centres GlobalReady d’Avance Clinical s’étend à grande vitesse et réunit désormais 2 000 centres membres | WAKE FOREST, Caroline du Nord et ADÉLAÏDE, Australie, 04 sept. 2024 (GLOBE NEWSWIRE) -- Avance Clinical, l’ORC primé et leader sur le marché des biotechnologies, a annoncé ce jour que 2 000 centres cliniques en Amérique du Nord avaient rejo... |
| 04.09.2024 | Avance Clinical GlobalReady 地點合作夥伴網絡迅速擴展至 2,000 個地點成員 | 北卡羅來納州威克森林和澳洲阿德萊德, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 屢獲殊榮的市場頂尖生物科技公司受託研究機構 (CRO) Avance Clinical 今天宣佈，在北美洲現已有 2,000 個臨床試驗地點加盟 Avance Clinical 的 GlobalReady 地點合作夥伴網絡 (GlobalReady Site Partnership Network)。
Avance Clinical 的行政總裁 Yvonne Lunge... |
| 04.09.2024 | Avance Clinical GlobalReady Site Partnership Network 迅速扩展至 2,000 个研究机构成员 | 北卡罗来纳州维克森林和澳大利亚阿德莱德, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 今日,屡获殊荣的市场领先生物技术 CRO 公司 Avance Clinical 宣布，北美地区 2,000 家临床研究机构已加入 Avance Clinical GlobalReady Site Partnership Network。
Avance Clinical 首席执行官 Yvonne Lungershausen 表示，2,000 家高素质研究机构的加入，将... |
| 01.09.2024 | Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000 Site Members | WAKE FOREST, N.C. and ADELAIDE, Australia , Sept. 01, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning market-leading CRO for biotechs, announced today that 2,000 clinical sites across North America had joined the Avance Clinical... |
| 27.08.2024 | Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value, and Proven Ability to Expedite Quality Clinical Programs | Avance Clinical streamlines its biotech clients' clinical trial operations, workflows, and data management, optimizing study efficiencies, minimizing costs, and accelerating trial timelines.
SAN ANTONIO, Aug. 27, 2024 /PRNewswire/ -- Frost ... |
| 15.08.2024 | Strategic Advantages of Early-Phase Oncology Clinical Development Across Australia and the USA, Upcoming Webinar Hosted by Xtalks | www.avancecro.com
In this free webinar, learn about the benefits of conducting early-phase oncology trials in Australia and later-phase trials in the USA. Attendees will gain insights into the streamlined regulatory processes in Australia t... |
| 21.09.2023 | AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES - SVP SCIENTIFIC AND REGULATORY AFFAIRS, AND DIRECTOR BUSINESS DEVELOPMENT | ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global... |
| 23.11.2021 | FDA approves pricey new treatment for ultra-rare and aggressive form of sarcoma | Horizon Therapeutics CEO Tim Walbert runs a rare disease company, but he’s also a patient. While his condition hasn’t been a secret, Walbert is stepping out for the first time as the face of rare disease in Horizon’s new corporate campaign ... |
| 23.11.2021 | Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron | Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for its neoantigen cancer vaccine, the Norwegian biotech has attracted yet another Big Pharma partner with deep pockets — and with it,... |
| 23.11.2021 | FDA approves pricey new treatment for ultra-rare and aggressive form of sarcoma | Forget the migraine marketing brand wars. When it comes to patients, many can’t even name one despite substantial advertising efforts, according to a new study from Phreesia that concludes CGRP migraine drugmakers still need to work on bran... |
| 23.11.2021 | At busy Visp site, Lonza will up microbial services by 50% | In an effort to up its development of microbial-derived proteins, Swiss CDMO Lonza will invest in its manufacturing capacities in its home country.
The extension will be good to go by the end of this year, the company... |
| 23.11.2021 | FDA approves pricey new treatment for ultra-rare and aggressive form of sarcoma | After a wild two-decade ride, the FDA has approved Takeda’s antiviral maribavir — now marketed as Livtencity — for cytomegalovirus, one of the most common viral infections experienced by transplant patients.
Takeda picked up maribavir a cou... |
| 23.11.2021 | Covid-19 roundup: WHO looks to boost production of antibody tests in lower-income countries; US government fights to uphold workplace vaccine mandate | While Europe is in the midst of a massive fourth Covid-19 surge, the UK has largely avoided the high levels of hospitalizations and deaths seen on the rest of the continent. And AstraZeneca CEO Pascal Soriot suggested Tuesday the reason for... |
| 23.11.2021 | A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research | Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.
The Natick, MA-based company announced in a statement this morning that it closed a Series A round, bri... |
| 23.11.2021 | Dragonfly gets Merck on second TriNKET candidate since 2018 collab; Chinese eye gene therapy developer nabs $60M | Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck — again.
After Merck licensed its first candidate from the platform back in Novemb... |
| 23.11.2021 | FDA approves pricey new treatment for ultra-rare and aggressive form of sarcoma | The FDA on Tuesday approved Aadi Bioscience’s first drug and the first treatment approved specifically for patients with an ultra-rare and aggressive form of sarcoma that occurs mostly in women.
The approval of the drug, k... |
| 23.11.2021 | FDA approves pricey new treatment for ultra-rare and aggressive form of sarcoma | President Biden’s nominee to run the FDA was hit with some tepid criticism back in 2016 for being too cozy with the biopharma industry because some of the trials he ran had industry sponsors and some of the funding he took was from industry... |
| 22.11.2021 | UPDATED: Xencor says goodbye to its former lead drug, selling all rights to Lonnie Moulder's new startup | More than three years after its lead program failed a Phase II study, Xencor is passing off the drug to an up-and-coming Hong Kong biotech.
Xencor sold exclusive worldwide rights for obexelimab, a bispecific targeting FcγRI... |
| 22.11.2021 | Bluebird bio may finally get a gene therapy approved in the US | Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a new drug candidate from Sosei Heptares.
Neurocrine outlined a deal that provides Sosei Hep... |
| 22.11.2021 | Biogen pulls PRIME designation for aducanumab in Europe; Merck closes merger with Acceleron | Following news last week that Biogen received “a negative trend vote” in Europe for its controversial Alzheimer’s drug aducanumab, the company has officially pulled out of the EU’s priority medicines scheme, known as ... |
| 22.11.2021 | BioCryst gets massive cash infusion to the tune of $350M, thanks to old and new investors | BioCryst is filling its coffers again — this time in $350 million cash with the help of both old and new investors.
The Durham, NC biotech reported this morning that it inked yet another deal alongside a familiar name — Royalt... |
| 22.11.2021 | NeuExcell heads east, landing suburban Philly headquarters | Ameet Mallik left Novartis to claim the CEO spot at Rafael Holdings back in May, taking the reins from founder Howard Jonas. Now — one month after a stock-crushing pivotal failure in pancreatic cancer that sent Rafael’s team back to the dra... |
| 22.11.2021 | NeuExcell heads east, landing suburban Philly headquarters | As activist investors champ at the bit for change at drug giant GlaxoSmithKline, the pharma giant has turned over many rocks to find an R&D success to present to its detractors. In NASH, a field strewn with failures, GSK hopes a new lic... |
| 22.11.2021 | NeuExcell heads east, landing suburban Philly headquarters | Back in June, Sanofi unveiled a big project to reshape its R&D around the future of mRNA, and followed that up Monday by taking a step toward achieving that goal.
The French drugmaker signed a deal with Chinese tech giant Baidu to acces... |
| 22.11.2021 | NeuExcell heads east, landing suburban Philly headquarters | Joan Perelló beat all the odds with his little Spanish biotech startup Sanifit.
Working on the far perimeter of the big US/European drug development scene, he took a drug born out of his PhD work and got enough seed cash to get started. Tha... |
| 22.11.2021 | The antibody discovery team at Twist bets on mouse model player in a boost to its portfolio | Twist Bioscience has come a long way since dipping its toes into the antibody discovery space a couple years ago, spinning out its first company just last week to take a Covid-19 antibody into the clinic. There’s plenty more... |
| 22.11.2021 | NeuExcell heads east, landing suburban Philly headquarters | Pennsylvania’s already well-established biotech scene got word of a boost last week with several announcements, including the building of a massive life sciences manufacturing center in Pittsburgh thanks to some fundin... |
| 22.11.2021 | NeuExcell heads east, landing suburban Philly headquarters | Most people know if they’re “Team Pfizer” or “Team Moderna,” but few know if they got the Comirnaty or Spikevax Covid-19 vaccine. Those are the brand names of Pfizer and Moderna vaccines, respectively, however they have yet to take hold wit... |
| 09.11.2021 | Riverside Invests in Avance Clinical, Accelerates Expansion Plans | The Riverside Company has invested in Avance Clinical (Avance), a leading premium Australian Contract Research Organisation (CRO) for international biotechs. The investment will further support the expansion of Avance’s clinical trials busi... |
| 11.09.2020 | GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 Therapeutics | Vijay Reddy
→ Vijay Reddy was seeking a return to the US when he left his role as CMO at London-based Autolus this summer. Philadelphia is that landing spot, as the T cell immunotherapy player Tmunity has put him in charge... |
